Phost’in Therapeutics and the Gianni Bonadonna Foundation To Present First Clinical Data on PhOx430, a First-In-Class GnT-V Inhibitor, at ESMO 2025

Montpellier, France and Milan, Italy – October 2, 2025 Phost’in Therapeutics SAS (Montpellier, France), Phost’in Therapeutics, a clinical-stage biotechnology company focused on the development of N-glycosylation inhibitors and the Fondazione Gianni Bonadonna, which provides scientific contribution and independent support, will jointly present a poster on interim clinical data from the PhAST trial at the European Society for Medical Oncology (ESMO) Annual Congress 2025, held October 17–21 in Berlin, Germany. Download the full Press Release

The release as fetched from its publisher. phostin.com ↗